| 雷帕霉素和罗格列酮对人乳腺癌细胞生长的影响* |
| |
| 引用本文： | 钟红,徐虓,马斌林,许永华,张东辉.雷帕霉素和罗格列酮对人乳腺癌细胞生长的影响*[J].中国肿瘤临床,2010,37(11):611-614. |
| |
| 作者姓名： | 钟红 徐虓 马斌林 许永华 张东辉 |
| |
| 作者单位： | 作者单位:新疆医科大学附属肿瘤医院乳腺头颈外科(乌鲁木齐市830011);①新疆医科大学第五附属医院肿瘤治疗中心;②兰州军区乌鲁木齐总医院动物实验科 |
| |
| 基金项目： | 新疆少数民族科技人才特殊培养计划科研项目资助 |
| |
| 摘 要： | 目的:探讨哺乳动物雷帕霉素靶蛋白（mammalian target of rapamycin，mTOR）特异性抑制剂雷帕霉素和过氧化物酶体增殖物激活受体γ（PPAR γ）激动剂罗格列酮对人乳腺癌细胞株MCF-7 体外培养的抑制作用，为临床靶向治疗提供试验依据。方法:取对数生长期的乳腺癌MCF-7 细胞株，按2.0 × 10 6细胞/孔接种24孔板，按照析因试验安排4 个试验组:①雷帕霉素组（8 ×10-5 mg/L）；②罗格列酮组（50μ mol/L）；③联合组；④、实验对照组（不做任何处理的常规培养细胞）。 各组各浓度分别设3 个复孔，实验重复3 次。采用MTT 比色法观察雷帕霉素和罗格列酮对体外培养的MCF-7 细胞系生长的抑制作用；应用流式细胞仪检测细胞凋亡和细胞周期变化。结果:罗格列酮和雷帕霉素均能有效的抑制体外培养的乳腺癌细胞株MCF-7 的生长，雷帕霉素的抑制率最大（P<0.05）。 联合用药不增加细胞生长抑制率（P<0.05）。 结论:体外培养抑制试验证明雷帕霉素、罗格列酮均能有效的抑制乳腺癌细胞株MCF-7 的生长。雷帕霉素联合罗格列酮不增加细胞凋亡。雷帕霉素和罗格列酮对MCF-7 细胞株的干预作用是通过周期阻滞完成的。
|
| 关 键 词： | 乳腺癌细胞株MCF-7 ?雷帕霉素 罗格列酮 靶向治疗 |
| 收稿时间： | 2009-03-09 |
Effects of Rapamycin and Rosiglitazone on the MCF-7 Cell Line, in vitro |
| |
| ZHONG Hong,XU Xiao,MA Bin-lin,XU Yong-hua,ZHANG Dong-hui.Effects of Rapamycin and Rosiglitazone on the MCF-7 Cell Line, in vitro[J].Chinese Journal of Clinical Oncology,2010,37(11):611-614. |
| |
| Authors: | ZHONG Hong XU Xiao MA Bin-lin XU Yong-hua ZHANG Dong-hui |
| |
| Affiliation: | Department of Breast and Neck Oncology Surgery Affiliated Tumour Hospital, Department of Tumor Therapy Center, the Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi 830011, China |
| |
| Abstract: | Objective: To investigate the depressant effect of two drugs, rapamycin and rosiglitazone, on the human breast cancer cell line MCF- 7, in vitro, in order to gain basic experimental data for clinical targeted therapy. Rapamycin is the specific inhibitor of the mammalian target of rapamycin (mTOR) protein and rosiglitazone is the activator of the peroxi -some prol i ferators-activated receptor γ (PPAR γ) Methods:MCF-7 cells, at logarithmic phase, were inoculated in a 24-well tissue culture plate at a concentration of 2.0 × 106 cells/well. Four experimental groups were assigned based on factorial de-sign, with the administration of drugs in three concentrations: low, medium and high. The drug concentrations were as fol-lows: Rapamycin group (4, 8, 10×10 -5 mg/L); Rosiglitazone group (25, 50, 100 μmol /L); Combination group (a combined ther-apy of 2 drugs with the low, medium and high concentrations); Control group (conventional cell culture without any treat-ment). Each drug concentration was set up in triplicate and the experiment was repeated three times. MTT colorimetric method was used to observe the inhibition of rapamycin and rosiglitazone on the growth of in vitro cultured MCF-7 cell lines. Flow cytometry was used to detect the change in apoptosis and cell cycle. Result:Both rosiglitazone and rapamycin can effectively inhibit the growth of in vitro MCF-7 cells, but the inhibitory rate of rapamycin ranked the highest (P<0.05). Rapamycin showed interference at the low and medium concentrations, while the apoptotic rate of the MCF-7 cells did not rise when the concentration was increased. The ratio of cell growth inhibition did not increase in the drug combination group (P<0.05), nor was there an increase of apoptosis ( P<0.05). There was no interaction in the drug combination of rapa-mycin and rosiglitazone at a low or medium concentration.Conclusions: The experiment of in vitro culture inhibition showed that both rapamycin and rosiglitazone can effectively inhibit the growth of human breast cancer cell line MCF- 7. Rapamycin administration combined with rosiglitazone did not increase the apoptosis of MCF- 7 cells cultured in vitro. The interference of rapamycin and rosiglitazone was completed by cycle blockage. |
| |
| Keywords: | |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
